5AM Partners VII, LLC sold $240k of SKYE
owner at Skye Bioscience, Inc.. 148,079 shares at an average of $1.62, traded Sep 22, 2026, filed Sep 24, 2026.
Score components
- +12Role10% owner
- +13Trade size$240k at market
- +20Share of holdings soldSold 100% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001231919-26-001224, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures II, L.P. | -27,612 | $1.65 | $46k | 114,851 | 21 d ago |
| Sep 22, 2026 | SOpen-market sale Common Stockindirect: By 5AM Co-Investors II, L.P. | -1,088 | $1.65 | $1,795 | 4,528 | 21 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By 5AM Ventures II, L.P. | -114,851 | $1.61 | $185k | 0 | 21 d ago |
| Sep 23, 2026 | SOpen-market sale Common Stockindirect: By 5AM Co-Investors II, L.P. | -4,528 | $1.61 | $7,290 | 0 | 21 d ago |
Related signals
Other insiders at Skye Bioscience, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 56Moderate | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $240k 148,079 shares | -104% | |
| 33Weak | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $65k 33,892 shares | -19% | |
| 36Weak | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $65k 33,892 shares | -19% | |
| 41Moderate | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $140k 375,840 shares | -26% | |
| 44Moderate | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $140k 375,840 shares | -26% | |
| 47Moderate | Skye Bioscience, Inc. | 5AM Partners VII, LLC owner | $801k 231,405 shares | -14% | |
| 50Moderate | Skye Bioscience, Inc. | Andrew J. Schwab director, owner | $801k 231,405 shares | -14% | |
| 45Moderate | Skye Bioscience, Inc. | Tuan Tu Diep Chief Development Officer | $98k 19,574 shares | -19% | |
| 54Moderate | Skye Bioscience, Inc. | Kaitlyn Arsenault Chief Financial Officer | $217k 43,396 shares | -21% | |
| 61Notable | Skye Bioscience, Inc. | Punit Dhillon Chief Executive Officer | $414k 82,910 shares | -20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.